1
|
De Sousa-Coelho AL, Rodriguez-Rodriguez R, Softic S, Jonker JW, Relat J. Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans. Front Endocrinol (Lausanne) 2023; 14:1253675. [PMID: 37608789 PMCID: PMC10441540 DOI: 10.3389/fendo.2023.1253675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Accepted: 07/17/2023] [Indexed: 08/24/2023] Open
Affiliation(s)
- A. L. De Sousa-Coelho
- Escola Superior de Saúde (ESS), Universidade do Algarve (UAlg), Faro, Portugal
- Algarve Biomedical Center Research Institute (ABC-RI), Universidade do Algarve (UAlg), Faro, Portugal
- Algarve Biomedical Center (ABC), Faro, Portugal
| | - R. Rodriguez-Rodriguez
- Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
| | - S. Softic
- Department of Pediatrics, Division of Pediatric Gastroenterology, Kentucky Children’s Hospital, and Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, United States
| | - J. W. Jonker
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - J. Relat
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
- Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, University of Barcelona, Santa Coloma de Gramenet, Spain
- Institute of Nutrition and Food Safety of the University of Barcelona (INSA-UB), Santa Coloma de Gramenet, Spain
| |
Collapse
|
2
|
Polonio E, Palomeras S, Bosch-Barrera J, Porta-Balanya R, Relat J, Ciurana J, Ruiz-Martínez S, Puig T. 1979MO Inhibition of fatty acid synthase (FASN) activity induces cytotoxicity on gefitinib- and osimertinib-resistant EGFR-mutated non-small cell lung cancer cells. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Urruticoechea A, Aguilar H, Cufi S, Cufi S, Turrado C, Relat J, Oliveras G, Benhamú B, Ortega-Gutiérrez S, López-Rodríguez M, Colomer R, Puig T. In Vivo and In Vitro Evidence of Antitumor Activity of UCM-Gi028 [Novel FASN Inhibitor] Against Trastuzumab-Resistant Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction. The vast majority of Her-2 positive advanced breast cancer patients develop resistance to Trastuzumab based therapies within the first year of treatment. We have previously shown that inhibition of Fatty Acid Synthase (FASN) activity, an enzyme overexpressed and hiperactivated in breast carcinoma leads to apoptosis in breast cancer cells and its effect is tightly linked to Her-2 signalling pathways. Here we show the anticancer effect of UCM-Gi028, the lead-compound of the first generation of a novel family of synthetic FASN inhibitors, both in vitro and in an animal model of Her-2 amplified breast cancer.Material and Methods. We analysed the cellular and molecular effects of UCM-Gi028 alone or in combination with lapatinib, erlotinib, trastuzumab and gefitinib in a Her-2 dependent breast cancer cell line (AU565) using epigallocatechin-3-gallate (EGCG), a natural inhibitor of FASN, as a comparator. We also generated a long-term trastuzumab resistant pool from AU565 cells (AU565TTZR pool) to evaluate the effect of UCM-Gi028 in this setting. We further characterize the toxicity profile, anti-cancer activity and pharmacodynamic markers in an athymic mice model of Her-2 positive breast cancer cell line xenograft tumors.Results. UCM-Gi028 shows marked synergic antitumoral activity combined with lapatinib, erlotinib, trastuzumab and gefitinib (p <0.05). Response to co-exposure of UCM-Gi028 plus growth-signal inhibitors was significantly correlated with induction of apoptosis and with decrease in the activation forms of HER-2, MAPK and AKT, as markers of drug activity. Importantly, AU565TTZR pool displayed increased sensitivity to UCM-Gi028 compared to previously known FASN inhibitors (EGCG and C75). In the Her-2 positive breast cancer animal model study no weight loss or other relevant toxicity were observed after long term (7 weeks) exposure to UCM-Gi-28. A group of UCM-Gi028-treated mice showed tumour regression compared to control and, importantly, responsive tumours showed inhibition of FASN activity, increased apoptosis and decreased HER-2, AKT and MAPK activity.Discussion. As compared to its related natural compound (EGCG), UCM-Gi-28 shows increased antitumor activity with a favourable toxicity profile, in contrast with other, highly toxic, synthetic FASN inhibitor (C75). UCM-Gi028 antitumour activity remains unchanged in trastuzumab resistant cells. UCM-Gi-28 warrants further pre-clinical and clinical development alone or in combination with other anticancer agents in Her-2 positive breast cancer.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5079.
Collapse
Affiliation(s)
| | - H. Aguilar
- 1Institut Catala d'Oncologia - IDIBELL, Barcelona, Spain
| | - S. Cufi
- 1Institut Catala d'Oncologia - IDIBELL, Barcelona, Spain
| | - S. Cufi
- 2Institut Catala d'Oncologia - IDIBGI, Spain
| | - C. Turrado
- 3Universidad Complutense de Madrid, Spain
| | - J. Relat
- 4Universitat de Barcelona, Spain
| | - G. Oliveras
- 2Institut Catala d'Oncologia - IDIBGI, Spain
| | | | | | | | - R. Colomer
- 5Centro Oncológico MD Anderson España, Spain
| | - T. Puig
- 6Universitat de Girona, Spain
| |
Collapse
|
4
|
Puig T, Relat J, Menéndez J, Porta R, Casals G, Marrero P, Haro D, Brunet J, Colomer R. 728 POSTER Differential inhibitory effects of epigallocatechin-3-gallate (EGCG) and C75 in cancer fatty acid metabolism. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70527-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|